DSM Biologics and MorphoSys AG signed a biopharmaceutical manufacturing agreement covering process development and cGMP manufacturing of MOR202, a fully human HuCAL antibody being studied for the treatment of multiple myeloma. DSM will manufacture MOR202 in its cGMP facilities in Groningen, the Netherlands. Financial details were not disclosed.     “Based on the positive experiences we have gained with the PER.C6 cell line and DSM’s manufacturing capabilities within our MOR103 lea...